Novartis Cash Flow Statement
NYSE: NVSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Novartis free cash flow
In fiscal 2025, Novartis generated $19.14 billion of operating cash flow and spent $1.55 billion on capital expenditures. That left free cash flow of $17.60 billion. Free cash flow was up 8.3% from the prior year's $16.25 billion.
Novartis returned $9.21 billion to shareholders through share repurchases, equal to 52% of free cash flow.
Summary generated from market data by MetaCap's automated system. Methodology
Novartis cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 13.97B | 11.94B | 14.85B | 6.96B | 24.02B | 8.07B | 11.74B | 12.61B | 7.70B | 6.70B |
| Net Income growth (YoY) | +16.99% | -19.62% | +113.57% | -71.04% | +197.58% | -31.23% | -6.95% | +63.75% | +15.00% | — |
| Stock-Based Compensation | 1.10B | 1.04B | 865.00M | 791.00M | 700.00M | 738.00M | 758.00M | 673.00M | 612.00M | 671.00M |
| Operating Cash Flow | 19.14B | 17.62B | 14.46B | 14.24B | 15.07B | 13.65B | 13.63B | 14.27B | 12.62B | 11.47B |
| Capital Expenditures | -1.55B | -1.37B | -1.06B | -916.00M | -1.07B | -1.27B | -1.38B | -1.25B | -1.32B | -1.86B |
| Investing Cash Flow | -4.88B | -7.51B | 5.60B | 1.47B | 4.21B | -13.18B | -2.23B | -5.59B | -3.12B | -3.44B |
| Share Repurchases | -9.21B | -8.33B | -8.72B | -10.65B | -3.06B | -2.84B | -5.53B | -2.04B | -5.49B | -1.11B |
| Debt Issued | 6.10B | 6.14B | — | 16.00M | 16.00M | 7.13B | 93.00M | 2.86B | 4.93B | 1.94B |
| Debt Repaid | -3.39B | -2.16B | -2.22B | -2.58B | -2.16B | -2.00B | -3.19B | -366.00M | -188.00M | -1.70B |
| Financing Cash Flow | -14.87B | -11.74B | -14.28B | -20.56B | -16.26B | -2.21B | -13.63B | -4.24B | -7.73B | -5.31B |
| Net Change in Cash | -24.00M | -1.93B | 5.88B | -4.89B | 2.75B | -1.45B | -2.16B | 4.41B | 1.85B | 2.33B |
| Free Cash Flow | 17.60B | 16.25B | 13.40B | 13.32B | 14.01B | 12.38B | 12.25B | 13.02B | 11.30B | 9.61B |
This table shows 10 annual periods of Novartis's cash flow statement, from FY 2025 back to FY 2016, across 11 line items including net income, stock-based compensation, operating cash flow. Values in USD; B = billions, M = millions. Fiscal periods follow NVS's reporting calendar. What is a cash flow statement?